Cis-platin in combination with low dose adriamycin and cyclophosphamide in advanced ovarian carcinoma. 1985

R H Verheijen, and L Beex, and D J Wagener, and P Kenemans

Between February 1979 and August 1981 20 patients with advanced ovarian carcinoma have been treated according to a mitigated PAC-V protocol: cis-platin 20 mg/m2 D1-5, adriamycin 35 mg/m2 D1 and cyclophosphamide 400 mg/m2 D1, and cyclophosphamide 400 mg/m2 b 7, q 28 days. Sixteen patients were evaluable with objective, measurable tumour-parameters. Minimal follow-up time was 21/2 years. Overall response rate was 50% (8/16) with complete response in 12.5% (2/16). Median duration of complete response was 40+ months, of partial response this was 16+ months. Two year survival rate was 9/16. Patients who had a complete debulking prior to PAC-V therapy or had not been treated before responded best (5/6 and 6/7 respectively). Thirteen patients indicated experiencing subjective improvement in their condition. Haematological, renal or neurological toxicity never caused threatening problems. In conclusion, a chemotherapy regimen containing a mitigated dose of adriamycin and cyclophosphamide next to full dose cis-platin yielded good tumour and patient response without severe toxicity.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

R H Verheijen, and L Beex, and D J Wagener, and P Kenemans
August 1980, Cancer,
R H Verheijen, and L Beex, and D J Wagener, and P Kenemans
January 1983, Cancer chemotherapy and pharmacology,
R H Verheijen, and L Beex, and D J Wagener, and P Kenemans
September 1984, British journal of obstetrics and gynaecology,
R H Verheijen, and L Beex, and D J Wagener, and P Kenemans
August 1977, Cancer treatment reports,
R H Verheijen, and L Beex, and D J Wagener, and P Kenemans
February 1981, Cancer,
R H Verheijen, and L Beex, and D J Wagener, and P Kenemans
January 1984, European journal of gynaecological oncology,
R H Verheijen, and L Beex, and D J Wagener, and P Kenemans
October 1982, Gynecologic oncology,
R H Verheijen, and L Beex, and D J Wagener, and P Kenemans
January 1980, Cancer chemotherapy and pharmacology,
Copied contents to your clipboard!